5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaChronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaEnrolling by invitationPhase 32026-10-07NCT07256392
A Study of Barzolvolimab in Patients With Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderActive, not recruitingPhase 22026-08-11NCT06727552
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticariaActive, not recruitingPhase 32026-03-25NCT06455202
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic diseaseActive, not recruitingPhase 32025-12-01NCT05681351
Eversense® Non-adjunctive Use Post Approval StudyNutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus, type 2 diabetes mellitusActive, not recruitingNot applicable2025-08-13NCT04836546